Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Sullivan

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Journal of Autoimmunity|January 16, 2007
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosisJorge Allina, Bin Hu, Daniel M Sullivan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinomaBert H O'Neil, Laura W Goff, John Sae Wook Kauh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignanciesJade Homsi, George R Simon, Chris R Garrett, et al.
Blood|March 3, 2016
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myelomaRachid C Baz, Thomas G Martin, Hui-Yi Lin, et al.
Breast Cancer Research : BCR|November 21, 2013
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumorsClifford Hudis, Charles Swanton, Yelena Y Janjigian, et al.
American Journal of Hematology|September 14, 2013
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myelomaRachid C Baz, Kenneth H Shain, Mohamad A Hussein, et al.
Cancer Medicine|December 31, 2015
Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignanciesDamon R Reed, Leo Mascarenhas, Kathleen Manning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic studyGeorge R Simon, Christopher R Garrett, Stephen C Olson, et al.
Journal of Hematology & Oncology|January 7, 2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumorsL Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, et al.
Oncotarget|March 24, 2016
A phase I study of indoximod in patients with advanced malignanciesHatem H Soliman, Susan E Minton, Hyo Sook Han, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Journal of Autoimmunity|January 16, 2007
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosisJorge Allina, Bin Hu, Daniel M Sullivan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinomaBert H O'Neil, Laura W Goff, John Sae Wook Kauh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignanciesJade Homsi, George R Simon, Chris R Garrett, et al.
Blood|March 3, 2016
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myelomaRachid C Baz, Thomas G Martin, Hui-Yi Lin, et al.
Breast Cancer Research : BCR|November 21, 2013
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumorsClifford Hudis, Charles Swanton, Yelena Y Janjigian, et al.
American Journal of Hematology|September 14, 2013
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myelomaRachid C Baz, Kenneth H Shain, Mohamad A Hussein, et al.
Cancer Medicine|December 31, 2015
Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignanciesDamon R Reed, Leo Mascarenhas, Kathleen Manning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic studyGeorge R Simon, Christopher R Garrett, Stephen C Olson, et al.
Journal of Hematology & Oncology|January 7, 2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumorsL Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, et al.
Oncotarget|March 24, 2016
A phase I study of indoximod in patients with advanced malignanciesHatem H Soliman, Susan E Minton, Hyo Sook Han, et al.
Pageof 9